- 12 Downloads
Ticlopidine1 is an inhibitor of platelet action that has been used in the treatment of a variety of disease states in which platelets play a prominent role. Studies in animals and man have demonstrated that ticlopidine is a potent inhibitor of platelet aggregation induced by adenosine diphosphate (ADP), and variably inhibits aggregation due to collagen, adrenaline (epinephrine), arachidonic acid, thrombin, and platelet activating factor. Inhibition of platelet aggregation is both dose- and time-related, with its onset of activity being 24 to 48 hours, its maximal activity occurring after 3 to 5 days, and its activity still being present 72 hours after a final dose. Ticlopidine also inhibits the release reaction of platelets, prolongs bleeding time, reduces plasma levels of platelet factor 4 and β-throm-boglobulin in patients in whom these proteins are elevated, and may also inhibit platelet adhesion, increase red cell ftltrability and decrease whole blood viscosity. In a large number of animal models, ticlopidine markedly inhibits thrombus formation or graft occlusion. Ticlopidine is well absorbed after oral administration. It is extensively metabolised and at least one of its metabolites is pharmacologically active.
Therapeutic trials in patients with chronic arterial occlusion due to thrombangitis obliterans or arteriosclerosis obliterans, post-myocardial infarction, cerebrovascular thromboembolic disease, subarachnoid haemorrhage, vascular shunts or fistulas for haemodialysis, and sickle cell disease have shown promise for the use of ticlopidine. However, trials of patients with intermittent claudication, angina pectoris, diabetes mellitus with micro-vascular disease, aortocoronary bypass grafts, and vascular prostheses have had conflicting results or have shown an unfavourable side effect profile. Further studies are clearly required to establish the role of ticlopidine in many of these areas, some of which are already in progress.
Overall, side effects occur in 10 to 15% of patients receiving ticlopidine. The most common side effects are gastrointestinal disturbances and skin rashes. Neither of these necessarily require discontinuation of therapy in most patients. Agranulocytosis, thrombocytopenia, and cholestatic jaundice have also been reported. Bleeding is infrequent except possibly in patients receiving ticlopidine prior to some surgical procedures.
In vitro, ticlopidine is a weak inhibitor of platelet aggregation, however it does inhibit Properties endothelial cell growth. After in vivo administration, ex vivo studies show that ticlopidine is a potent inhibitor of platelet aggregation induced by ADP, however, its ability to inhibit aggregation due to thrombin, collagen, arachidonic acid, adrenaline and platelet activating factor is very variable. Unlike other antiplatelet agents, ticlopidine inhibits both the first and second phases of platelet aggregation, and its effects are both dose- and time-related. The onset of its effects is 24 to 48 hours, with maximal antiaggregating effect measurable after 3 to 5 days of dosing, and its effects are still present up to 72 hours after a final dose. Ticlopidine also prolongs the bleeding time by 2- to 5-fold in a dose-and time-related fashion and inhibits the platelet release reaction. Ticlopidine’s effects on prostaglandins are complex and not fully understood; malondialdehyde synthesis in response to collagen, thrombin, or adrenaline is partially inhibited (as with aspirin), serum thromboxane concentrations are reduced, and the effects of prostacyclin enhanced. Ticlopidine may act by modifying platelet membrane affinity for fibrinogen and/or ADP. Its effects on platelet adhesion are again variable. In patients with elevated β-thromboglobulin and platelet factor 4 ticlopidine therapy reduces the levels of these proteins. Ticlopidine generally prolongs platelet survival in patients with disease states in which it is reduced, especially in patients shortly after an acute myocardial infarction. Ticlopidine binds to red cell membrane in vitro and reduces the tendency to haemolyse in hypotonic solution. In high concentrations, it delays sickling of red cells of patients with sickle cell disease. Red cell deformability and filtrability may also be increased by ticlopidine. Whole blood, but not plasma, viscosity may also be decreased; thus, rheological activity may contribute to ticlopidine’s overall effects. In a large number of coagulation-dependent animal models, thrombosis induced by chemical, mechanical or electrical methods, or by implantation of artificial surfaces was almost invariably markedly inhibited. In addition, in models of coagulation where platelets play little or no role, ticlopidine consistently prevented pathological changes.
Approximately 80 to 90% of an oral dose of ticlopidine is absorbed, with peak plasma concentrations occurring after 1 to 3 hours. Peak concentrations after a single 500mg dose are approximately 0.6 to 0.8 mg/L, whereas a single 1000mg dose has produced peaks of about 2.1 mg/L. Peak ticlopidine concentrations after 250mg doses were given twice daily for 21 days were about 0.9 mg/L. Ticlopidine is rapidly and extensively metabolised. Overall recovery of a radiolabelled dose is about 85%, with unchanged ticlopidine representing only about 2%. At least one metabolite is active.
Elimination half-lives of 24 to 33 hours have been reported, but single- and multiple-dose studies have demonstrated a rapid 4-fold reduction in plasma concentrations over 4 to 12 hours. Thus, the true half-life of ticlopidine is not known. No studies on the pharmacokinetics of ticlopidine have been performed in patients with decreased renal or hepatic function.
Ticlopidine has been studied in patients with various disease states in which platelets play a major role. In patients with atherosclerotic disease and intermittent claudication, conflicting results have been obtained, with some studies demonstrating an improvement in maximum walking distance and pain-free distance, and others demonstrating no benefit. Five large multicentre trials are under way to help define a role for ticlopidine in this disease. In patients with chronic arterial occlusion due to thrombangitis obliterans or arteriosclerosis obliterans, ticlopidine therapy has been associated with a clear improvement in lower extremity ulcer healing rate and vascular improvements.
In patients with angina pectoris, ticlopidine has produced mixed results although the weight of evidence would suggest little, if any, role for ticlopidine in these patients. However, in patients started on ticlopidine within 12 hours of an acute myocardial infarction, platelet survival was improved and cardiac enzyme concentrations were reduced compared to placebo. A role for ticlopidine in the post-infarction period is promising, although large controlled studies are needed.
In a large multicentre study, patients with a recent transient ischaemic attack were treated with ticlopidine, with the result of fewer cerebrovascular or cardiovascular ‘events’ than observed with aspirin therapy. Similarly, patients with cerebral infarction treated with ticlopidine suffered fewer relapses than those receiving dipyridamole. In patients with subarachnoid haemorrhages, treated surgically within 3 days of the haemorrhage, ticlopidine reduced the incidence of neurological deficit plus mortality at the time of discharge. Those with angiographically documented vasospasm were especially benefited by ticlopidine, despite a lack of effect of the drug on vasospasm per se. Further large studies are in progress to compare ticlopidine and aspirin.
In studies examining the effects of ticlopidine in patients with diabetes mellitus, there has been no evidence of reduced progression of retinopathy, nephropathy, neuropathy, or cardiovascular illness.
In uraemic patients in whom AV shunts or fistulas were inserted for vascular access, presurgical initiation of ticlopidine has reduced the incidence of vascular occlusion, and thus the need for clot removal or reconstruction of the vascular device. Additionally, ticlopidine may reduce the degree of leucocyte count drop during dialysis, improve dialyser function, and reduce the dose of heparin needed to prevent clotting during dialysis.
In patients undergoing open heart surgery, preoperative initiation of ticlopidine reduces the degree of platelet count drop during extracorporeal circulation. However, the effect of the drug on peri- and postoperative bleeding has been varied, with some studies demonstrating an increase in the degree of bleeding and a requirement for reoperation. Very variable results have been achieved in the use of ticlopidine to prevent occlusion of coronary bypass grafts. Several trials have reported no clinical benefit, whereas the largest study showed significant decreases in graft occlusion compared with placebo. In any event, the initiation of ticlopidine before these operations should be approached with great caution. Patients with ‘Dacron’ prosthetic vascular grafts have undergone clinical trials with ticlopidine, but the drug has not demonstrated efficacy in reducing the degree of platelet adhesion to the graft membrane.
In patients with primary glomerulonephritis ticlopidine reduced the degree of proteinuria as well as dipyridamole, but has a greater potential to reduce the degree of haematuria, and a greater effect on improving creatinine clearance.
In two studies in patients with sickle cell disease, ticlopidine reduced the incidence, duration, and severity of infarctive crises, and reduced the degree of pulmonary arteriovenous shunting.
Approximately 10 to 15% of patients receiving ticlopidine have experienced side effects, the most common of which have been gastrointestinal complaints and skin rash. Approximately 10% experience gastrointestinal discomfort, nausea, or diarrhoea, occasionally requiring discontinuation of therapy. Administration of the drug with food may reduce the problem. Bleeding during ticlopidine therapy is an unusual side effect, but is dangerous in patients who must undergo surgery or another invasive procedure. In patients undergoing AV access insertion, there has been no increase in bleeding, but in patients undergoing open heart surgery, the risk of bleeding may be increased with ticlopidine.
Agranulocytosis, neutropenia, thrombocytopenia, and erythroleukaemia have been reported during therapy with ticlopidine. Elevation of liver function tests are unusual with ticlopidine therapy, but occasionally cholestatic jaundice or hepatitis have been reported. Ticlopidine may increase total serum cholesterol, as well as LDL- and VLDL-cholesterol and other lipoproteins, without affecting HDL-cholesterol.
In three separate trials, the combination of aspirin and ticlopidine seemed to display additive to synergistic activity as platelet inhibitors. Corticosteroids, given orally or as a single intravenous injection, can reduce the prolonged bleeding time caused by ticlopidine, without altering its inhibition of platelet aggregation.
Dosage and Administration
In the majority of clinical trials, the dose of ticlopidine has been 500 mg/day, given as 2 equally divided doses per day, generally with meals. In some studies, 750 mg/day has been given, and this higher dose may be more efficacious in some settings. Dosing of ticlopidine prior to surgery may possibly increase the risk of operative bleeding.
KeywordsAspirin Platelet Aggregation Sickle Cell Disease Dipyridamole Ticlopidine
Unable to display preview. Download preview PDF.
- Abe T, Kuramoto A, Yasunaga K, Sakuragawa N, Maekawa T, et al. Clinical evaluation of ticlopidine in the inhibition of platelet function — a multiclinic double blind study in comparison with aspirin. Abstract 1300. Thrombosis and Haemostasis 46: 410, 1981Google Scholar
- Akazawa Y, Mori H, Ohishi M, Koide M, Azuma T. Anti-platelet effect of ticlopidine in diabetics (part I). Japanese Archives of Internal Medicine 30: 29–36, 1983Google Scholar
- Altman R, Rouvier J, Vasalo S. Bleeding time (BT): influence of different drugs. Thrombosis and Haemostasis 50: 134, 1983Google Scholar
- Arcan JC, Destors JM. Controlled clinical trial of ticlopidine in patients suffering from intermittent claudication. In The International Committee on Thrombosis and Haemostasis 32nd Annual Meeting and the Mediterranean League Against Thromboembolic Diseases, 9th Congress, Jerusalem, 1–6 Jun, 1986, Abstract 315. Thrombosis Research (Suppl. 6): 159, 1986Google Scholar
- Ashida S-I, Abiko Y. Inhibition of platelet aggregation by a new agent, ticlopidine. Thrombosis and Haemostasis 40: 542–550, 1978Google Scholar
- Aubert D, Bernat A, Ferrand JC, Maffrand JP, Szygenda E, et al. Pharmacological profile of PCR 3787: a metabolite of ticlopidine. From the Seventh International Congress of Thrombosis, October, Valencia, Spain, 1982Google Scholar
- Avellone G, Mandala V, Novo S, Cannioto F, Ranelli G. Effect of ticlopidine on malondialdehyde in patients with ischaemic heart disease: comparison with low dose aspirin. Abstract 384.Google Scholar
- From the Seventh International Congress on Thrombosis, Valencia, Spain, October 13–16, 1982Google Scholar
- Avellone G, Pinto A, Davi G, Di Garbo V, Strano A. Ticlopidine induced haemorheological changes in patients suffering from atherosclerosis obliterans of the lower limb. International Congress of Angiology, June 9–14, Athens, Greece, 1985Google Scholar
- Baele G, Rottiers R, Rubens R, Priem H. Effect of ticlopidine on plasma beta-thromboglobulin and platelet factor-4 levels in diabetes mellitus. Abstract 252. From the Seventh International Congress on Thrombosis, Valencia, Spain, October 13–16, 1982Google Scholar
- Bando H, Yamashito T, Kimura K, Tsubura E. Effect of antiplatelet agents on natural killer activity of spleen cells in mice. Igaku no Ayumi 127: 662–663, 1983Google Scholar
- Bando H, Yamashito T, Matsunaga Y, Tsubura E. Role of platelets in cancer metastasis formation — inhibitory effect of antiplatelet therapy on NK activity, and enhancing effect of PDGF on tumor growth and metastasis. Ketsueki to Myakkan (Blood Vessel) 15: 258–262, 1984Google Scholar
- Bastida E, Escolar G, Almirall L, Garrido M, Ordinas A. Ticlopidine inhibits platelet thrombogenicity induced by SKNMC, a human neuroblastoma cell line. Thrombosis and Haemostasis 54: P1434, 1985Google Scholar
- Bernat A, Delebasse D, Maffrand JP, Tissinier A, Vallee E. Role of coagulation in the antithrombotic effect of ticlopidine. Abstract 0222. Thrombosis and Haemostasis 50: 75, 1983Google Scholar
- Bernat A, Millou E, Delebassee D, Tissiner A, Vallee E, et al. Antithrombotic effect of ticlopidine/aspirin combination in rats. Thrombosis and Haemostasis 54: P1440, 1985aGoogle Scholar
- Bernat A, Vallée E, Maffrand JP, Gordon J. Role of platelets in experimental thrombosis induced by venous stasis. Proceedings of the XIth Congress of Thrombosis and Haemostasis, Brussels, 1987Google Scholar
- Bonne C, Battais E. Ticlopidine and adenylate cyclase. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 88–96, 1984Google Scholar
- Bourde C, Eschwege E, Verry M. Controlled clinical trial of an antiaggregating agent, ticlopidine, in vascular ulcers of the leg. Abstract 0271. Thrombosis and Haemostasis 46: 91, 1981Google Scholar
- Bowles MJ, Khurmi NS, O’Hara MJ, Raftery EB. An evaluation of objective indices of myocardial ischaemia for clinical trials of anti-anginal drugs. British Journal of Clinical Pharmacology 17: 213P, 1984Google Scholar
- Bruno JJ, Yang D, Taylor LA, Feamster C. Role of platelet cAMP and prostaglandin synthesis in platelet aggregation inhibition by ticlopidine hydrochloride. Thrombosis and Haemostasis 46: 66, 1981Google Scholar
- Bruno JJ. The mechanism of action of ticlopidine. Thrombosis Research (Suppl.) 4: 59–67, 1983Google Scholar
- Bruno JJ, Molony BA. Ticlopidine. In Scriabine (Ed.) New drugs annual: cardiovascular drugs, pp. 295–316, Raven Press, New York, 1983Google Scholar
- Bruno JJ, Chang L-F, McSpadden MM, Yang D. The effect of oral ticlopidine on arachidonic acid products in human platelets. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 76–87, 1984Google Scholar
- Bruno JJ, Yang D, Taylor LA. Differing effects of ticlopidine and two prostaglandin synthetase inhibitors on maximum rate of ADP-induced aggregation. Thrombosis and Haemostasis 46: 412, 1981Google Scholar
- Buxon AO, Castejon J, Coloma F, Marti JL. Efecto de la ticlopidina sobre la agregacion plaquetaria. Medicina Espagnol 78: 58–61, 1979Google Scholar
- Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, et al. Clinical and biological double-blind study of ticlopidine in preventive treatment of sickle-cell disease. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 199–212, 1984Google Scholar
- Cazenave J-P, Wiesel M-L, Hemmendinger S. Current treatment for thrombotic diseases. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 24–47, 1984Google Scholar
- Chevolet C, Grosdent JC, Reiters GM, Dresse A. Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine. Archives of International Pharmacodynamics 259: 310–311, 1982Google Scholar
- Choe DT, Povalski HJ. Effects of sulfinpyrazone, dipyridamole, ticlopidine, aspirin, and indomethacin on initiation and growth rate of experimental arterial thrombosis in the rat. Federation Proceedings 40: 772, 1981Google Scholar
- Claas FHJ, de Fraiture WH, Meyboom RHB. Thrombopenie causee par des anticorps induits par la ticlopidine. Nouvelle Revue Française de Hematologie 26: 323–324, 1984Google Scholar
- Cliveden PB, Salzman EW. Platelet metabolism and the effect of drugs. In Bowie & Sharp (Ed.) Hemostatis and thrombosis, Vol. 2, pp. 1–35, Butterworths, London, 1985Google Scholar
- Cloarec M, Caillard P, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Abstract no. 316. Thrombosis Research (Suppl. 6): 160, 1986Google Scholar
- Davi G, Muzzo MP, Novo S, Mazzola A, Mendola G, et al. Effects of ticlopidine on platelet function in peripheral vascular disease patients. Seventh International Congress on Thrombosis, Abstract no. 383. Valencia, Spain, 1982Google Scholar
- Davi G, Pinto A, Francavilla G, Campisi D, Paterna S, et al. Ticlopidine in arteriosclerosis obliterans of the lower limbs: a double blind cross-over study. International Congress of Angiology, Athens, Greece, June 9–14, 1985Google Scholar
- de Gramont A, Canuel C, Krulik M, Bauters F, Degos L, et al. Toxicite hematologique de la ticlopidina? Nouvelle Revue Française de Hematologie 24: 35–37, 1982Google Scholar
- Di Minno G, Palladino M, Pannain M, Scillitani A, Turco S, et al. Normalization by ticlopidine of the abnormally high fibrinogen binding to platelets from retinopathic diabetics. Thrombosis and Haemostasis 54: 0380, 1985bGoogle Scholar
- Driot E, Maffrand JP, Vallee E. Platelet-subendothelium interaction: effect of ticlopidine. Abstract 1199. Thrombosis and Haemostasis 50: 379, 1983Google Scholar
- Dunn FW, Soria J, Soria C, Thomaidis A, Lee H, et al. In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 97–104, 1984Google Scholar
- Ell S, Mihindukulasuriya JCL, O’Brien JR, Polak A, Vernham G. Ticlopidine in the prevention of blockage of fistulae and shunts. Abstract 332 from the Seventh International Congress on Thrombosis, p. 180, Valencia, Spain, October 13–16, 1982Google Scholar
- Ellis DJ. Treatment of intermittent claudication with ticlopidine. Abstract addendum. Presented at the International Committee on Thrombosis and Haemostasis 32nd Annual Meeting and the Mediterranean League Against Thromboembolic Diseases, 9th Congress, Jerusalem, 1–6 Jun, 1986Google Scholar
- Ellis DJ, Roe RL, Bruno JJ, Cranston BJ, McSpadden MM. The effects of ticlopidine hydrochloride on bleeding time and platelet function in man. Abstract 0543. Thrombosis and Haemostasis 46: 176, 1981Google Scholar
- Escolar G, Bastida E, Rodriguez J, Garrido M, Ordinas A. Effects of ticlopidine on platelet adherence. Thrombosis and Haemostasis 54: P1432, 1985Google Scholar
- Eugene C, Lefebvre JF, Gury B, Quevauvillieres J. Hepatite cholestatique: role vraisemblable de la ticlopidine. Semaine des Hôpitaux Paris 59: 2923–2924, 1983Google Scholar
- Gent M, Ellis D. Canadian American Ticlopidine Study (Cats) in thromboembolic stroke. Agents and Actions Supplements, Vol. 15, Ticlopidine: Quo Vadis? 15: 283–296, 1984Google Scholar
- Geroulanos S, Walter P, Cogan C, Binkert M, Turina M, et al. Platelet inhibitors. Abstract 285 from the Seventh International Congress on Thrombosis, Valencia, Spain, October 13–16, 1982Google Scholar
- Godard P, Zini R, Metay A, Tillement JP. The fate of ticlopidine in the organism: distribution and elimination of ticlopidine 14C after a single intravenous injection in the rat. European Journal of Drug Metabolism and Pharmacokinetics 3: 67–71, 1978Google Scholar
- Goldman M, Aukland A, Hall C, Hawker RJ, McCollum CN. Ticlopidine compared to aspirin plus dipyridamole as an antithrombotic agent. Abstract 246 from the Seventh International Congress on Thrombosis, p. 135, Valencia, Spain, October 13–16, 1982Google Scholar
- Gordon JL. Overview: pharmacology of ticlopidine. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 108–115, 1984Google Scholar
- Goyan JE. Adverse reactions in man. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 116–125, 1984Google Scholar
- Hass WK, Kamm B. The North America Ticlopidine Aspirin Stroke Study: structure, stratification variables, and patient characteristics. Agents and Actions Supplements, Vol. 15, Ticlopidine: Quo Vadis? 15: 273–278, 1984Google Scholar
- Hong YG, Kang JK. The effect of ticlopidine hydrochloride on regional cerebral blood flow in acute cerebral infarction. An experimental model in cats. K’at’ollik Tachak Ulhakpu Nonmunjip 38: 159–172, 1985Google Scholar
- Houtsmuller AJ, Vermeulen JACM, Klompe M, Zahn KJ, Henkes HE, et al. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents and Actions Supplements, Ticlopidine: Quo Valis? 15: 219–229, 1984Google Scholar
- Iovine C, d’Avenia V, Turco S, Mattioli PL, di Minno G. Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation. Agents and Actions Supplements, Vol. 15, Ticlopidine: Quo Vadis? 105–107, 1984Google Scholar
- Johnson M, Heywood JB. Possible mode of action of ticlopidine: a novel inhibitor of platelet aggregation. Thrombosis and Haemostasis 42: 367, 1979Google Scholar
- Johnson M, Walton PL, Cotton RC, Strachan CJL. Pharmacological evaluation of ticlopidine. A novel inhibitor of platelet function. Thrombosis and Haemostasis 38: 64, 1977Google Scholar
- Kadota I, Tanaka K, Yoshida K, Shiraishi S, Hattori M. Effect of ticlopidine on increased platelet aggregation in diabetes associated with vascular complications. Japanese Archives of Internal Medicine 30: 7–13, 1983Google Scholar
- Katsumura T. Therapeutic effect of ticlopidine for ischemic leg ulcers. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 167–172, 1984Google Scholar
- Kawagoe S, Seino Y, Tei H, Munakata J, Yamaguchi A, et al. Platelet TXA2 synthesizing activity in ischemic heart disease and effect of ticlopidine. Thrombosis and Haemostasis 54: P397, 1985Google Scholar
- Kikuchi M, Ikeda Y, Murakami H, Watanabe K, Ando Y. Effects of cilostazol, a new antithrombotic agent, on platelet functions ex vivo: randomized, double-blind, crossover study with aspirin and ticlopidine. Thrombosis and Haemostasis 54: P804, 1985Google Scholar
- Knudsen JB, Kjoller E, Gormsen J. The effect of ticlopidine, propranolol, and verapamil on stress-induced platelet-activation. Abstract 1469. Thrombosis and Haemostasis 50: 458, 1983Google Scholar
- Kobayashi I, Takeuchi M, Takemiya T, Osawa M, Maruyama S. Enhancement of platelet function in ischemic cerebrovascular disorders (CVD) and its effect on ticlopidine treatment. Abstract 1491. Thrombosis and Haemostasis 50: 463, 1983Google Scholar
- Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, et al. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis — a multicenter collaborative double bünd study. Thrombosis Research 30: 255–261, 1980Google Scholar
- Kumada M, Dohi K, Fujii Y, Hanatani M, Ishikawa H. The effects of anti-platelet agents on renal functions and the modes of their antiplatelet action in primary glomerulonephritis. Abstract 79. Japanese Journal of Medicine 24: 335, 1985Google Scholar
- Lacaze B, Ferrand C, Pepin O. Induction of DIC by Russell’s viper venom in the rat: preventive activity of ticlopidine on consumption coagulopathy. Abstract 0172. Thrombosis and Haemostasis 42: 75, 1979Google Scholar
- Lalo-Keraly C, Delautier D, Delabassee D, Chignard M, Benveniste J. Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets. Thrombosis Research 34: 463–471, 1984Google Scholar
- Lasierra J, Areval A, Vilades E, Hebrero J, Espinosa H. Effect of the ticlopidin (sic) in the risk of thromboembolic disease in the postoperation. Abstract 185 from the Seventh International Congress on Thrombosis, Valencia, Spain, October 13–16, 1982Google Scholar
- Lecrubier C, Girard P, Noire P, Samama M. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 60–75, 1984Google Scholar
- Limet R, David J-L, Magotteaux P, Larock M-P, Rigo P. Prevention of aortocoronary bypass occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts — a double-blind study. Journal of Thoracic and Cardiovascular Surgery 94, in press, 1987Google Scholar
- Lonsdorfer J, Castaigne JP, Lenormand E, Otayeck A, Bougi P, et al. Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisis. Agents and Actions Supplements, Vol. 15, Ticlopidine: Quo Vadis? 15: 213–218, 1984Google Scholar
- Maekawa T, Kobayashi N. Antiplatelet therapy. In “Recent trends in treatments for thrombosis.” Blood Vessel 13: 92–96, 1982Google Scholar
- McKenna R, Galante J, Molony B, Kamm B. Failure of ticlopidine hydrochloride to prevent DVT in orthopaedic patients. Blood 62: 304a, 1983Google Scholar
- Mazue G, Berthe J, Combes M, Garbay TM, Gouy D, et al. Toxicological studies of ticlopidine in laboratory animals. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 126–135, 1984Google Scholar
- Meschengieser S, Woods A, Schattner M, Lazzari MA. Antiplatelet action of ticlopidine on normal patients and thrombotic patients. Abstract 292 from the Seventh International Congress on Thrombosis, p. 159, Valencia, Spain, October 13–16, 1982Google Scholar
- Mion C, Chong G, Nguyen QV. Haemodialysis without heparin, a possible benefit from the use of ticlopidine in end stage renal disease haemodialysis patients. Abstract 0820. Thrombosis and Haemostasis 46: 262, 1981Google Scholar
- Mirouze J (on behalf of the TIMAD study group). Ticlopidine in the secondary prevention of early diabetes-related microangiography: protocol of a multicenter therapeutic study (TIMAD study). Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 230–258, 1984Google Scholar
- Moore PK. Prostanoids and platelets. In Moore (Ed.) Prostanoids: pharmacological, physiological and clinical relevance, pp. 79–99, Cambridge University Press, Cambridge, 1985Google Scholar
- Mortensen SA, Knudsen JB, Hjelms E, Efsen F. Pre- and postoperative platelet inhibition with ticlopidine in connexion (sic) with coronary artery bypass surgery (CABG). Abstract 1. European Heart Journal 4 (Suppl. Apr), 1983Google Scholar
- Murphy KP, Dewanjee MK, Fuster V, Didisheim P, Kaye MP. Effect of ticlopidine on platelet deposition in Gore-Tex and autologous vein grafts. Reference 0542. Thrombosis and Haemostasis 46: 175, 1981Google Scholar
- Mustard JF, Kinlough-Rathbone RL, Packham MA. Mechanisms of thrombosis. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 9–23, 1984Google Scholar
- Nagatsuka K, Uyama O, Nakabayashi O, Kusonoki S, Isaka Y, et al. Effect of ticlopidine on platelet aggregation and arachidonic acid metabolism: studies in healthy subjects and patients with cerebral thrombotic infarction. Journal of Japanese College Angiology 23: 499–500, 1983Google Scholar
- Najean Y, Poirier O. Beta-thromboglobulin and platelet factor 4 in polycythemia patients treated by ticlopidine. Acta Haematologia 72: 83–89, 1984Google Scholar
- Neri Serneri GG, Gensini GF, Favilla S, Breschi C, Abbate R. Ticlopidine activity on platelet function in patients with enhanced platelet aggregation: a short term cross over study. Abstract 181 from the Seventh International Congress on Thrombosis, p. 102, Valencia, Spain, October 13–16, 1982Google Scholar
- Neumann V, Cove DH, Shapiro LM, George AJ, Kenny MW, et al. Effect of ticlopidine on platelet function and blood rheology in diabetes mellitus. Clinical Hemorheology 3: 13–21, 1983Google Scholar
- Novo S, Cosentino F, Strano A. Effects of ticlopidine and captopril alone and in combination in hypertensives with claudicatio intermittens. International Congress of Angiology, Athens, Greece, June 9–14, 1985Google Scholar
- Numano F, Numano F. Arteriosclerosis and antiplatelet therapy. Drugs of Today 21: 41–49, 1985Google Scholar
- Ono H, Mizukami M, Kitamura K, Kikuchi H, and the cooperative study group in Japan. Subarachnoid hemorrhage. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 259–272, 1984Google Scholar
- Ono S-e, Ashida S-i, Abiko Y. Hemorheological effect of ticlopidine in the rat. Thrombosis Research 31: 549–556, 1983Google Scholar
- Panak E, Blanchard J, Roe RL. Evaluation of the antithrombotic efficacy of ticlopidine in man. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 148–166, 1984Google Scholar
- Paolucci S, Buttinelli C, Prencipe M, Lenzi GL. Ticlopidine and platelet aggregates in cerebrovascular patients. Current Therapeutic Research 34: 1044–1049, 1983Google Scholar
- Pflüger N, Goebel N, Turina M, Rothlin M. Influence of the antiaggregant ticlopidine on the patency of aorto-coronary bypass grafts. Abstract 71. European Heart Journal 2(Suppl. A): 208, 1981Google Scholar
- Picard-Fraire C. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents and Actions Supplements. Ticlopidine: Quo Vadis? 15 (Suppl.): 68–75, 1984Google Scholar
- Pogliani EM, Colombi M, Cristoforeei G, Valenti G, Miradoli R, et al. Antiplatelet drugs in haemodialysis. Abstract 334 from the Seventh International Congress on Thrombosis, p. 281, Valencia, Spain, October 13–16, 1982Google Scholar
- Pupita F, Rotatori P, Frausini G, Gaggi S. Clinical pharmacology of ticlopidina. International Congress of Angiology, Athens, Greece, June 9–14, 1985Google Scholar
- Rajah SM, Salter MCP, Crow MJ, Davison AM. Evaluation of five antiplatelet regimens in haemodialysis: prevention of platelet deposition and thrombus formation. Abstract 0174. Thrombosis and Haemostasis 50: 61, 1983Google Scholar
- Reece AH, Walton PL. Inhibition of intimai proliferation of rabbit aorta by ticlopidine. Abstract 0873. Thrombosis and Haemostasis 42: 367, 1979Google Scholar
- Rieger JS, Picho JL-T. Effect of ticlopidine on the prevention of relapses of cerebrovascular ischemic disease. Medical Clinics (Barcelona) 82: 62–64, 1984Google Scholar
- Rigaud M, Rabinovitch H, Durand J, Breton JC, Rigaud G. Action of ticlopidine on the oxygenated metabolism of arachidonic acid in the mouse peritoneal macrophage. Abstract 0546. Thrombosis and Haemostasis 46: 176, 1981Google Scholar
- Roe RL, Ellis DJ, Bruno JJ, Cranston B. A comparison of the effects of four antiplatelet drugs on bleeding time and platelet function in man. Abstract B31. Clinical Pharmacology and Therapeutics, page 264, 1982Google Scholar
- Stiegler H, Hess H, Trampisch H-J. The course of peripheral obliterative arterial disease under the influence of the platelet-function inhibitor ticlopidine. Abstract 594. European Heart Journal (Suppl. June): 138, 1984Google Scholar
- St-Marc Girardin M-F, Cordonnier C. Ictere cholestatique et agranulocytose dus a la ticlopidine. Gastroentérologie Clinique et Biologique, pp. 716–717, 1982Google Scholar
- Strano A, Davia G, Cannizzaro S, Timpone S, Alaimo P, et al. Effects of administration of ticlopidine and low dose aspirin on platelet function in IHD patients. Thrombosis and Haemostasis 54: P394, 1985Google Scholar
- Stuart J, Aukland A, George AJ, Hurlow RA. Effect of platelet inhibition with ticlopidine on fibrinolytic activity in patients with atherosclerosis. Haemostasis 11(Suppl. 1): 99, 1982Google Scholar
- Takegoshi T, Ono K, Matsubayashi K, Hasimoto F. Sano M. Metabolic disposition of ticlopidine hydrochloride, a new antithrombotic agent, in rats. Pharmacometrics 19: 349–361, 1980Google Scholar
- Tanaka K, Kohga S, Ogawa H, Ishihara M, Tanaka N. Effect of ticlopidine on blood-borne metastasis. In Hellman et al. (Eds) Metastasis: clinical and experimental aspects, Vol. 4, pp. 147–152, Martinus Nijhoff, The Hague, 1980Google Scholar
- Tekeres M, Sarosi I, Juricskay I, Losoncsy H, Nagy I. Effect of longterm ticlopidine therapy on the Theological properties of blood. Abstract 215 from the Seventh International Congress on Thrombosis, p. 120, Valencia, Spain, October 13–16, 1982Google Scholar
- Thompson IW, Fiskerstrand C, Burnett E, Anderton JL. The effect of ticlopidine on coagulation parameters and blood cell counts during haemodialysis. Abstract 286 from the Seventh International Congress on Thrombosis, p. 156, Valencia, Spain, October 13–16, 1982Google Scholar
- Tohgi H. The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 279–282, 1984Google Scholar
- Velasco A, Dominguez MJ, Olabarria I, Iriarte J. 12 months of treatment with ticlopidine in atherosclerotic intermittent claudication. Clinical and biological evaluation. International Congress of Angiology, Athens, Greece, June 9–14, 1985Google Scholar
- Verstraete M. Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg ulcers. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 173–187, 1984Google Scholar
- Vicari AM, Penasa L, Pozza G. Clinical effectiveness of ticlopidine in diabetic subjects: a double-blind study. Abstract 379 from the Seventh International Congress on Thrombosis, p. 203, Valencia, Spain, October 13–16, 1982Google Scholar
- Vincent JE, Zijlstra FJ, Veerdonk MAMvd, Bonta IL. The effect of ticlopidine on the aggregation of rat blood platelets and on the formation of metabolites from arachidonic acid and 8,11,14-eicosatrienoic acid in rat platelets during aggregation, and in the rat kidney. Agents and Actions 12: 377–381, 1982PubMedGoogle Scholar
- Willis AL, Fisher JM, Donegan D, Smith DL. Anti-platelet effects of ticlopidine are not diminished by EFA deficiency or indomethacin administration. Abstract 0545. Thrombosis and Haemostasis 46: 176, 1981Google Scholar
- Yajima M, Namba K, Nomura S, Tsukada T, Nishiyama K, et al. Preventive effects of phthalazinol, ticlopidine and aspirin for thromboxane-induced myocardial infarction in rabbits. Abstract 0996. Thrombosis and Haemostasis 50: 313, 1983Google Scholar
- Yasuda K, Tanabe T, Hasimoto M, Suzuki S, Shimizu T, et al. Effect of cilostazol, a new antithrombotic drug, on small arterial replacement. Thrombosis and Haemostasis 54: P1246, 1985Google Scholar
- Yoshikawa T, Murakami M, Furakawa Y, Deguchi M, Kato H, et al. Effect of ticlopidine, dipyridamole, and aspirin on endotoxin-induced disseminated intravascular coagulation in rats. Abstract 0927. Thrombosis and Haemostasis 50: 293, 1983aGoogle Scholar
- Yoshikawa T, Murakami M, Furukawa Y, Takemura S, Kondo M. Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats. Thrombosis and Haemostasis 50: 190–192, 1983bGoogle Scholar
- Yunis AA, Arimura GK, Lo L. Comparative effects of ticlopidine and analogues on in vitro myeloid colony (CFU-GM) growth. Agents and Actions Supplements, Ticlopidine: Quo Vadis? 15: 136–147, 1984Google Scholar